Pelvic actinomycosis

Pelvic Actinomycosis

⚠️

Key Point: Pelvic actinomycosis is a rare, chronic, slowly progressive granulomatous infection caused by Actinomyces israelii and related species. It is strongly associated with prolonged intrauterine device (IUD) use. It can mimic pelvic malignancy clinically and radiologically, causing diagnostic delays. Treatment requires prolonged high-dose penicillin — often 6–12 months. Surgery is reserved for abscess drainage or cases refractory to antibiotics.

Introduction & Australian Epidemiology

Actinomycosis is a chronic suppurative infection caused by gram-positive anaerobic or microaerophilic filamentous bacteria of the genus Actinomyces. The organism is a normal commensal of the oral cavity, gastrointestinal tract, and female genital tract. Disease occurs when mucosal barriers are disrupted, allowing invasion of adjacent tissue.

Pelvic actinomycosis is the second most common form after cervicofacial disease, accounting for approximately 20% of cases. It is rare, with exact Australian incidence data unavailable, but case series from tertiary gynaecology units confirm ongoing presentations, predominantly in women of reproductive age with long-term IUD use. IUD-associated cases have increased as long-acting reversible contraception (LARC) use has grown.

The hallmark of actinomycosis is its capacity to cross tissue planes, form sinus tracts, and produce sulfur granules (macroscopic colonies of the organism). This behaviour, combined with a dense fibrotic host reaction, leads to the formation of indurated masses that closely resemble ovarian, endometrial, or colorectal malignancy on imaging and clinical examination.

Microbiology & Pathophysiology

Causative Organisms

Actinomyces israelii is the predominant species in pelvic disease. Other species include A. naeslundii, A. odontolyticus, A. meyeri, and A. gerencseriae. These are slow-growing, gram-positive, non-spore-forming, filamentous bacteria — not true fungi despite the historical "-myces" nomenclature.

Growth characteristics: Strict or facultative anaerobe; grows slowly on culture (7–21 days); requires anaerobic/CO₂-enriched atmosphere.
Sulfur granules: Pathognomonic macroscopic yellow-white granules (0.1–5 mm) composed of tangled filaments with peripheral clubs — represent bacterial microcolonies.
Polymicrobial: Often accompanied by co-infecting bacteria (e.g. Fusobacterium, Prevotella, Streptococcus species) that may contribute to virulence through synergy.

Pathophysiology

Pelvic actinomycosis follows ascending infection from the endocervical canal, facilitated by IUD-associated disruption of the normal vaginal/cervical mucosal barrier. The infection spreads contiguously — not haematogenously — invading the uterus, fallopian tubes, ovaries, and parametrial tissues. It characteristically crosses fascial planes (hence involvement of bladder, rectum, and abdominal wall in advanced cases). The host mounts a dense fibrotic response, producing a woody-hard pelvic mass with central abscess formation.

ℹ️

IUD association: Risk increases sharply after >3 years of IUD use. However, most women with Actinomyces-like organisms (ALOs) detected on cervical cytology while using an IUD do NOT have clinical disease — only a small minority develop invasive actinomycosis.

Clinical Presentation & Diagnostic Criteria

Symptoms

Presentation is typically insidious with months to years of symptoms before diagnosis. The chronic, indolent course and imaging findings that mimic malignancy contribute to diagnostic delay.

Chronic pelvic pain: Dull, constant lower abdominal/pelvic pain — most common presenting symptom.
Pelvic mass: Firm, non-tender or mildly tender adnexal or uterine mass on examination and imaging — frequently mistaken for ovarian cancer or fibroid.
Vaginal discharge: Persistent mucopurulent or malodorous discharge; may contain sulfur granules (pathognomonic when present).
Constitutional symptoms: Low-grade fever, malaise, weight loss, and night sweats — more common in advanced or abscess-forming disease.
Bowel/urinary symptoms: Frequency, dysuria, or altered bowel habit if rectum or bladder is involved.
Sinus tracts: Spontaneous cutaneous fistulae discharging sulfur granules — rare in pelvic disease but pathognomonic when present.

Clinical Clues

⚠️

Consider actinomycosis when: A pelvic mass is found in a woman with long-term IUD use (>3 years), particularly if associated with chronic pelvic pain, weight loss, or prior pelvic infections. Biopsy/histopathology is diagnostic if malignancy is suspected.

Investigations

Essential

Histopathology

Gold standard for diagnosis. Demonstrates characteristic sulfur granules with surrounding acute inflammatory infiltrate and fibrosis. Filamentous gram-positive organisms visible on Gram stain and modified Ziehl-Neelsen stain. Obtained via laparoscopic biopsy, endometrial curettage, or USS/CT-guided core biopsy of pelvic mass. Differentiates from malignancy.
Essential

CT Pelvis & Abdomen (with contrast)

First-line imaging. Shows complex adnexal/pelvic mass with irregular borders, central necrosis/abscess, infiltration of adjacent structures (rectum, bladder, pelvic sidewall), and fat stranding. Findings can mimic advanced ovarian or colorectal cancer — biopsy required for differentiation.
Essential

Microbiology — Culture

Culture of pus, discharge, or biopsy material under strict anaerobic conditions for 7–21 days. Low sensitivity (~50%) — negative culture does not exclude diagnosis. Alert microbiology laboratory to suspected actinomycosis (prolonged incubation required). PCR/16S rRNA sequencing increasing availability in Australian reference labs.
Essential

Inflammatory Markers

FBC (leucocytosis with neutrophilia), CRP (elevated — often markedly so), ESR (elevated). Non-specific but useful for monitoring treatment response. Anaemia of chronic disease common in protracted cases.
Available

Tumour Markers (CA-125, CEA, CA19-9)

Often elevated in pelvic actinomycosis — can further mimic ovarian malignancy. Useful to order to document pre-treatment elevation; should normalise with successful antibiotic therapy. Persistently elevated markers after treatment warrant further malignancy workup.
Available

Cervical Cytology (Pap/Cervical Screen)

May show Actinomyces-like organisms (ALOs) in IUD users — fluffy, cotton-wool-like bacterial clumps. ALOs on cytology alone do NOT diagnose actinomycosis and do not require treatment in asymptomatic women. Clinical correlation required.
Available

MRI Pelvis

Superior soft tissue characterisation for surgical planning. Delineates extent of pelvic involvement, infiltration of rectum/bladder/pelvic floor, and relationship to vascular structures. Useful pre-operatively or when CT findings are indeterminate.

Clinical Assessment & Staging

No validated severity scoring exists for pelvic actinomycosis. Clinical staging guides treatment intensity and the role of surgery alongside antibiotics.

LOCALISED

Endometritis / Salpingitis

Infection confined to the uterus and/or fallopian tubes without abscess or mass formation. ALOs on cytology with mild symptoms. IUD removal alone with antibiotic course may suffice.

Outpatient or short admission; oral penicillin 6–12 months

MODERATE

Tubo-ovarian Abscess / Mass

Pelvic mass with abscess formation involving adnexae. May involve parametrium. CT-guided drainage feasible in selected cases. IV antibiotics initially, transition to oral after clinical improvement.

Inpatient IV antibiotics ± drainage; prolonged oral course

ADVANCED

Extensive Pelvic / Multi-organ

Disease crossing fascial planes to involve rectum, bladder, pelvic sidewall, or abdominal wall. Fistula formation. Extensive surgical debridement may be required. Long-term IV penicillin followed by oral therapy for ≥12 months.

MDT: gynaecology, colorectal surgery, urology, ID specialist

Antimicrobial Therapy

ℹ️

IUD Management: Remove the IUD early in treatment — this is essential. In mild localised disease with IUD removal and short antibiotic course, some patients achieve cure without prolonged therapy. In established abscess or mass, IUD removal must accompany prolonged antibiotic treatment.

💊

Benzylpenicillin (Penicillin G) IV

Penicillin G · β-lactam · First-line induction

Adult Dose 18–24 million units (10.8–14.4 g) per day by continuous IV infusion OR 3–4 million units (1.8–2.4 g) IV every 4 hours

Duration (IV) 2–6 weeks IV, then transition to oral when clinically improving

Indication Moderate-severe disease; abscess formation; unable to tolerate oral therapy

Renal Adj. Reduce dose if eGFR <30 mL/min (risk of neurotoxicity with high doses)

PBS Status ✓ PBS Listed

💊

Amoxicillin (Oral Step-Down / Maintenance)

Amoxil® · β-lactam · First-line oral

Adult Dose 500 mg – 1 g orally three times daily (TDS)

Total Duration 6–12 months total (IV + oral combined). Localised disease: minimum 6 months. Extensive disease: up to 12+ months. Reassess at 3 months with imaging.

Step-down criteria Clinical improvement (afebrile, pain improving, CRP falling), tolerating oral intake

Renal Adj. Reduce to 500 mg BD if eGFR 10–30 mL/min; 500 mg daily if eGFR <10

PBS Status ✓ PBS Listed

Penicillin Allergy

💊

Doxycycline (Penicillin allergy — non-anaphylaxis)

Doryx® · Tetracycline · Alternative

Adult Dose 100 mg orally twice daily

Duration 6–12 months (as per disease extent)

Notes Less clinical data than penicillin. Avoid in pregnancy. Take with food to reduce oesophagitis risk.

PBS Status ✓ PBS Listed

💊

Clindamycin (Severe penicillin allergy / anaerobic coverage)

Dalacin C® · Lincosamide · Alternative

IV Dose 600 mg IV every 8 hours

Oral Dose 300–450 mg orally four times daily

Duration 6–12 months; monitor for Clostridioides difficile colitis

PBS Status ✓ PBS Listed

Role of Surgery

CT/USS-guided drainage: Preferred approach for accessible abscesses — drains pus, provides microbiological material, avoids major surgery. Can be repeated if needed.
Laparoscopic/open surgery: Reserved for diagnostic uncertainty (suspected malignancy), treatment failure after adequate antibiotics, fistula formation, or bowel/urinary obstruction.
Extent of resection: Conservative surgery preferred — wide resection of friable actinomycotic tissue with primary antibiotic cover. Hysterectomy/salpingo-oophorectomy may be required for extensive uterine disease.
Post-operative antibiotics: Continue prolonged antibiotic therapy even after complete surgical resection to prevent recurrence.

Monitoring Parameters

Weeks 2–4

Clinical reassessment: fever curve, pain scores, CRP/ESR trend. IV-to-oral switch decision based on clinical improvement. IUD removal confirmed. Confirm microbiology results and sensitivities (may take 2–3 weeks from culture submission).

Month 3

Repeat CT pelvis/abdomen with contrast to assess radiological response. Expect significant reduction in mass size and resolution of abscess. CRP/ESR should be normalising. Tumour markers if elevated at baseline — should be falling.

Month 6

Reassess for treatment duration. If complete clinical and radiological response, consider ceasing therapy. If residual mass or persistent elevation of inflammatory markers, continue to 12 months. ID specialist review recommended for all complex cases.

Month 12

Final reassessment. Confirm radiological cure (resolution of mass or dense fibrous residual without active disease features). Discuss alternative contraception if IUD removed. Monitor for relapse — rare with adequate treatment duration.

Special Populations

🤰 Pregnancy

Pelvic actinomycosis in pregnancy is exceedingly rare. IUD-related disease should theoretically not occur during pregnancy (IUD use precludes conception), but pre-existing undiagnosed disease may manifest during pregnancy. Penicillin is safe throughout pregnancy.

Treatment: IV benzylpenicillin followed by oral amoxicillin — both safe in all trimesters.
Avoid: Doxycycline (teratogenic in 2nd/3rd trimester); metronidazole in 1st trimester.
Surgery: Defer elective surgery to post-partum if possible; emergency drainage for life-threatening abscess is appropriate at any gestational age.

🛡️ Immunocompromised

Immunocompromised patients (HIV, transplant recipients, systemic corticosteroids) may have more aggressive or disseminated actinomycosis with atypical presentations. Diagnosis requires a higher index of suspicion.

Treatment: Same antibiotic regimen; however, treatment duration should be extended to 12 months minimum given risk of relapse.
Disseminated disease: Haematogenous spread to liver, lung, or CNS is more likely in severely immunocompromised — whole-body CT recommended at diagnosis.
Drug interactions: Clindamycin and doxycycline may interact with antiretrovirals — ID specialist consultation recommended.

🫘 Renal Impairment

High-dose benzylpenicillin IV requires dose reduction in significant renal impairment to avoid neurotoxicity (encephalopathy, myoclonus, seizures).

eGFR 30–50 mL/min: Reduce benzylpenicillin to 12–18 million units/day. Amoxicillin oral: 500 mg TDS (no change).
eGFR 10–29 mL/min: Benzylpenicillin 6–12 million units/day; amoxicillin 500 mg BD.
eGFR <10 / dialysis: Specialist nephrology and ID input required; amoxicillin 500 mg daily or after each dialysis session.

👴 Elderly Patients

Pelvic actinomycosis in post-menopausal women is less common but occurs, particularly with retained IUDs inserted years prior. The differential with pelvic malignancy is even more critical in this age group.

Diagnosis: Histopathological confirmation is essential before committing to prolonged antibiotic therapy — malignancy must be excluded first.
Treatment: Standard penicillin regimen; renal function monitoring given age-related decline in GFR. Consider dose reduction proactively.
Polypharmacy: Review drug interactions with prolonged antibiotics in the context of other medications. Doxycycline increases photosensitivity risk.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Pelvic actinomycosis is rare in all populations; no specific epidemiological data for Aboriginal and Torres Strait Islander peoples exists. However, barriers to gynaecological care — including geographic isolation, stigma around pelvic symptoms, and limited access to imaging and specialist services — may contribute to delayed diagnosis and more advanced disease at presentation in remote communities.

Delayed Diagnosis

Chronic pelvic pain and pelvic masses may be attributed to other causes or under-investigated in remote settings. Low threshold for specialist gynaecology referral is essential when chronic pelvic symptoms persist, particularly in women with long-term IUD use. Telehealth and fly-in-fly-out specialist services can facilitate access.

IUD Use & Monitoring

LARC including IUDs is widely promoted in remote Aboriginal health care settings for unintended pregnancy prevention. Regular IUD reviews (annual checks) with removal and replacement after 5–10 years are important to minimise prolonged IUD-associated risk. Ensure IUD users have access to follow-up.

Prolonged Treatment Adherence

Six to twelve months of oral antibiotics requires significant adherence support. Engagement of Aboriginal Health Workers, case coordination, medication blister packaging, and reminder systems improve completion rates. Community-controlled health organisations play a central role.

Cultural Safety

Gynaecological consultations require culturally safe environments with female practitioners and interpreters where available. Ensure informed consent processes are culturally appropriate when surgical procedures are discussed. Acknowledge that pelvic examination may carry cultural sensitivities.

Antibiotic Stewardship (ACSQHC NSQHS Standard 3)

⚠️

Prolonged therapy is intentional: The required 6–12 month antibiotic duration reflects the biology of actinomycosis — not antibiotic failure. Premature cessation is the most common cause of relapse. Document rationale in the medical record and communicate clearly to the patient and community prescribers.

Narrow-spectrum penicillin: Actinomyces species remain reliably susceptible to penicillin — no resistance has been reported. Broad-spectrum agents are not required for Actinomyces itself.
Polymicrobial co-pathogens: If co-infecting organisms are identified (e.g. Escherichia coli, anaerobes), temporary broadening of cover may be appropriate during the induction phase — guided by culture and sensitivities.
Avoid empirical broad-spectrum therapy indefinitely: Once Actinomyces is confirmed as the primary pathogen, de-escalate to penicillin monotherapy.
Shared care planning: Engage the patient's GP for long-term oral amoxicillin prescribing after hospital discharge. Provide a written antimicrobial management plan including planned duration, monitoring schedule, and stop date.

Pelvic actinomycosis